Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lung disease study probes hidden environmental triggers

NCT ID NCT07577115

Knowledge-focused Sponsor: Istituto Clinico Humanitas Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how things in the environment and at work might affect people with interstitial lung diseases (a group of lung conditions). Researchers will ask 1,000 adults with a new diagnosis about their exposures to things like pollution, chemicals, and dust. The goal is to learn how common these exposures are and how they might impact the disease, which could help doctors better understand and manage these conditions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Dec 2034

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Eligible participants will be identified during routine ILD outpatient visits and enrolled after written informed consent. Baseline data collection will occur at the time of enrollment. Diagnostic consistency will be ensured through multidisciplinary discussion (MDD). The contribution of exposure history to diagnostic refinement and additional testing will be systematically recorded. Data will be prospectively collected using a standardised CRF at baseline and every 6 months (±2 months), in line with clinical practice. A structured questionnaire assessing environmental and occupational exposures will be: * Administered at baseline * Re-administered at each follow-up visit Exposure domains will include: * Occupational exposures (dusts, fibres, chemicals) * Domestic exposures (mould, animals, biomass) * Hobbies and recreational exposures * Drug-related exposures Exposure relevance will be evaluated during MDD.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years old * Any gender * Any race * Ability to give informed consent according to ICH/EU GCP, and national/local regulations. * New diagnosis of ILD according to classified according to American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias Exclusion Criteria: * Sarcoidosis * Primary diagnosis of COPD and/or Asthma

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Exposure occupational are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypersensitivity pneumonitis idiopathic pulmonary fibrosis interstitial lung disease pulmonary fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Exposure occupational Exposure to chemical pollution, occupational Exposure to environmental pollution Exposure to household air pollution Hypersensitivity pneumonitis Idiopathic pulmonary fibrosis (IPF) ILD Ild progression and exposure to indoor environnemental risk Ild progression and exposure to outdoor polluants Interstitial lung disease due to systemic disease (disorder) Interstitial lung disease due to systemic disease (telomere biology disorder) Occupational exposure Progressive pulmonary fibrosis

Contacts and locations

Locations

  • Humanitas research hospital

    Rozzano, Italy, 20089, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.